公开(公告)号：US11327082B2

公开(公告)日：2022-05-10

申请号：US16646798

申请日：2018-09-13

Applicant: B.R.A.H.M.S GmbH

Inventor： Aline Pehla ,  Stefan Kirsch ,  Darius Wilson

IPC: G01N33/74 ,  G01N33/86

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.

公开(公告)号：US20210405070A1

公开(公告)日：2021-12-30

申请号：US16972509

申请日：2019-06-06

Applicant: B.R.A.H.M.S GMBH

Inventor： Darius Wilson ,  Aline Pehla ,  Stefan Ebmeyer ,  Frauke Dreyer

IPC: G01N33/74

Abstract: The invention relates to a method for the diagnosis, prognosis, prediction, risk assessment and/or risk stratification of a subsequent trauma-related complication in a polytrauma patient, comprising providing a sample of said patient, wherein the sample is isolated from the patient after the polytrauma, determining a level of pro ADM or fragment(s) thereof in said sample, wherein said level of pro ADM or fragment(s) thereof correlates with the likelihood of a subsequent trauma-related complication

公开(公告)号：US12000845B2

公开(公告)日：2024-06-04

申请号：US17710369

申请日：2022-03-31

Applicant: B.R.A.H.M.S GmbH

Inventor： Aline Pehla ,  Stefan Kirsch ,  Darius Wilson

IPC: G01N33/74 ,  G01N33/86

CPC classification number: G01N33/74 ,  G01N33/86 ,  G01N2800/222 ,  G01N2800/50 ,  G01N2800/52

Abstract: The invention relates to a method for determining, diagnosis, prognosis, treatment guidance, treatment monitoring, risk assessment and/or risk stratification of patients with abnormal platelet levels comprising providing a sample of said patient, determining a level of proadrenomedullin (proADM) or fragment(s) thereof in said sample, wherein said level of proADM or fragment(s) thereof correlates with the abnormal platelet levels in said patient. In embodiments of the invention, a level of proADM or fragment(s) thereof of high severity indicates low platelet levels in the subject and subsequent initiating or modifying a treatment of the patient to improve said condition. In some embodiments of the invention the method comprises determining a level of one or more additional markers in a sample isolated from the patient, such as the level of platelets, the level of PCT or fragment(s) thereof, one or more markers of thrombocytopenia and/or one or more markers of an inflammatory response.